Christopher B. Ehrlich - 25 Aug 2021 Form 4 Insider Report for eFFECTOR Therapeutics, Inc.

Role: Director
Signature: /s/ Michael Byrnes, Attorney-in-Fact for Chris Ehrlich
Issuer symbol: EFTR on OTC
Transactions as of: 25 Aug 2021
Net transactions value: $0
Form type: 4
Filing time: 27 Aug 2021, 18:53:30 UTC
Next filing: 05 Oct 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EFTR	Common Stock	Conversion of derivative security	$0	+142,168		$0.000000	142,168	25 Aug 2021	By Locust Walk Partners LLC	F1
transaction	EFTR	Common Stock	Conversion of derivative security	$0	+1,034		$0.000000	1,034	25 Aug 2021	By Locust Walk Partners LLC	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EFTR	Class B Common Stock	Disposed to Issuer	$0	-132,832	-48%	$0.000000	142,168	25 Aug 2021	Common Stock	132,832		By Locust Walk Partners LLC	F1, F3, F4, F5
transaction	EFTR	Class B Common Stock	Conversion of derivative security		-142,168	-100%		0	25 Aug 2021	Common Stock	142,168		By Locust Walk Partners LLC	F1, F3
transaction	EFTR	Class B Common Stock	Disposed to Issuer	$0	-966	-48%	$0.000000	1,034	25 Aug 2021	Common Stock	966		By Locust Walk Partners LLC(	F2, F3, F4, F5
transaction	EFTR	Class B Common Stock	Conversion of derivative security		-1,034	-100%		0	25 Aug 2021	Common Stock	1,034		By Locust Walk Partners LLC	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares held directly by the Sponsor, of which Locust Walk Partners LLC ("LWP") is a member. LWP has allocated these shares to the reporting person.
F2	Represents shares held directly by the Sponsor, of which LWP is a member. LWP has allocated these shares to the reporting person's spouse.
F3	On August 25, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of May 26, 2021 (the "Merger Agreement"), by and among the Issuer (f/k/a Locust Walk Acquisition Corp.), Locust Walk Merger Sub, Inc. ("Merger Sub"), and eFFECTOR Therapeutics, Inc. ("Old eFFECTOR"), Merger Sub merged with and into Old eFFECTOR with Old eFFECTOR surviving as a wholly owned subsidiary of the Issuer (the "Merger"). In connection with and upon consummation of the Merger, each of the Issuer's outstanding shares of Class B Common Stock automatically converted into one share of Class A Common Stock and such shares of Class A Common Stock were automatically reclassified in shares of common stock.
F4	Pursuant to an agreement by and between the Issuer and Locust Walk Sponsor, LLC (the "Sponsor"), concurrent with the consummation of the Merger, these shares of Class B Common Stock were forfeited to the Issuer immediately prior to the Merger.
F5	As a former principal of the manager of the Sponsor, the reporting person previously reported all securities held by the Sponsor. As of the date hereof, the reporting person is no longer a principal of the entity with control over the securities held by the Sponsor, accordingly, this report only includes securities to the extent of the reporting person's and his spouse's pecuniary interest therein.